JP6022159B2 - 抗ｈｐｖワクチン - Google Patents
抗ｈｐｖワクチン Download PDFInfo
- Publication number
- JP6022159B2 JP6022159B2 JP2011520506A JP2011520506A JP6022159B2 JP 6022159 B2 JP6022159 B2 JP 6022159B2 JP 2011520506 A JP2011520506 A JP 2011520506A JP 2011520506 A JP2011520506 A JP 2011520506A JP 6022159 B2 JP6022159 B2 JP 6022159B2
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- vaccine
- dose
- months
- vlp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002566 papillomavirus vaccine Drugs 0.000 title description 9
- 229960005486 vaccine Drugs 0.000 claims description 171
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 151
- 241000701806 Human papillomavirus Species 0.000 claims description 65
- 239000002671 adjuvant Substances 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 239000000427 antigen Substances 0.000 description 35
- 102000036639 antigens Human genes 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 35
- 238000000034 method Methods 0.000 description 24
- 230000005847 immunogenicity Effects 0.000 description 21
- 238000002255 vaccination Methods 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 238000009021 pre-vaccination Methods 0.000 description 16
- 230000028993 immune response Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 13
- 229940124897 Gardasil Drugs 0.000 description 12
- 229940124957 Cervarix Drugs 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 description 8
- 238000005571 anion exchange chromatography Methods 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 229910052782 aluminium Inorganic materials 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- -1 aluminum compound Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000001728 nano-filtration Methods 0.000 description 3
- 230000005937 nuclear translocation Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000550 effect on aging Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 231100001222 nononcogenic Toxicity 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- 101150070189 CIN3 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 108700025391 Human papillomavirus type 6 L1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 238000013320 baculovirus expression vector system Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 101150005988 cin2 gene Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940032313 prophylactic HPV vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8510108P | 2008-07-31 | 2008-07-31 | |
| US61/085,101 | 2008-07-31 | ||
| US17656109P | 2009-05-08 | 2009-05-08 | |
| US61/176,561 | 2009-05-08 | ||
| PCT/EP2009/059820 WO2010012780A1 (en) | 2008-07-31 | 2009-07-29 | Vaccine against hpv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529475A JP2011529475A (ja) | 2011-12-08 |
| JP2011529475A5 JP2011529475A5 (enExample) | 2012-09-13 |
| JP6022159B2 true JP6022159B2 (ja) | 2016-11-09 |
Family
ID=41139260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520506A Active JP6022159B2 (ja) | 2008-07-31 | 2009-07-29 | 抗ｈｐｖワクチン |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20110189229A1 (enExample) |
| EP (1) | EP2318042B1 (enExample) |
| JP (1) | JP6022159B2 (enExample) |
| KR (1) | KR20110053340A (enExample) |
| CN (1) | CN102159239A (enExample) |
| AU (1) | AU2009275909A1 (enExample) |
| BR (1) | BRPI0916732B1 (enExample) |
| CA (1) | CA2732436C (enExample) |
| CO (1) | CO6341567A2 (enExample) |
| DK (1) | DK2318042T3 (enExample) |
| DO (1) | DOP2011000031A (enExample) |
| EA (1) | EA201170264A1 (enExample) |
| ES (1) | ES2519490T3 (enExample) |
| HR (1) | HRP20141063T1 (enExample) |
| IL (1) | IL210977A0 (enExample) |
| MA (1) | MA32554B1 (enExample) |
| MX (1) | MX2011001218A (enExample) |
| NZ (1) | NZ590919A (enExample) |
| PE (1) | PE20110327A1 (enExample) |
| PL (1) | PL2318042T3 (enExample) |
| PT (1) | PT2318042E (enExample) |
| RS (1) | RS53607B1 (enExample) |
| SI (1) | SI2318042T1 (enExample) |
| SM (1) | SMT201400170B (enExample) |
| WO (1) | WO2010012780A1 (enExample) |
| ZA (1) | ZA201100889B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2768172A1 (en) | 2009-06-25 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Novel compositions |
| CN102178944A (zh) * | 2010-09-17 | 2011-09-14 | 大连雅立峰生物制药有限公司 | 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用 |
| CN102229660B (zh) * | 2011-05-25 | 2015-04-22 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| EP3191505A2 (en) * | 2014-09-11 | 2017-07-19 | Cadila Healthcare Limited | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2628693C1 (ru) * | 2016-11-10 | 2017-08-21 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) | РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ |
| US20210302427A1 (en) * | 2020-03-31 | 2021-09-30 | Shuhari Group, LLC | Secure Immunity Information Transmission System And Network |
| KR20260109890A (ko) * | 2024-01-04 | 2026-07-13 | 사이안백 엘엘씨 | 백신 조성물에 증가된 안정성을 제공하는 개선된 제형 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP1732598A4 (en) * | 2003-12-31 | 2009-08-26 | Pharmexa Inc | TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| KR20070029254A (ko) * | 2004-06-16 | 2007-03-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 |
| AR054259A1 (es) * | 2005-04-26 | 2007-06-13 | Glaxosmithkline Biolog Sa | Vacuna contra virus de papiloma humano (hpv) |
-
2009
- 2009-07-29 ES ES09781248.1T patent/ES2519490T3/es active Active
- 2009-07-29 AU AU2009275909A patent/AU2009275909A1/en not_active Abandoned
- 2009-07-29 BR BRPI0916732-3A patent/BRPI0916732B1/pt active IP Right Grant
- 2009-07-29 DK DK09781248.1T patent/DK2318042T3/da active
- 2009-07-29 PE PE2011000104A patent/PE20110327A1/es not_active Application Discontinuation
- 2009-07-29 KR KR1020117004436A patent/KR20110053340A/ko not_active Withdrawn
- 2009-07-29 WO PCT/EP2009/059820 patent/WO2010012780A1/en not_active Ceased
- 2009-07-29 PT PT97812481T patent/PT2318042E/pt unknown
- 2009-07-29 CA CA2732436A patent/CA2732436C/en active Active
- 2009-07-29 NZ NZ590919A patent/NZ590919A/xx not_active IP Right Cessation
- 2009-07-29 EP EP09781248.1A patent/EP2318042B1/en active Active
- 2009-07-29 US US13/056,452 patent/US20110189229A1/en not_active Abandoned
- 2009-07-29 CN CN200980135875XA patent/CN102159239A/zh active Pending
- 2009-07-29 SI SI200931047T patent/SI2318042T1/sl unknown
- 2009-07-29 MX MX2011001218A patent/MX2011001218A/es not_active Application Discontinuation
- 2009-07-29 HR HRP20141063AT patent/HRP20141063T1/hr unknown
- 2009-07-29 RS RS20140613A patent/RS53607B1/sr unknown
- 2009-07-29 PL PL09781248T patent/PL2318042T3/pl unknown
- 2009-07-29 EA EA201170264A patent/EA201170264A1/ru unknown
- 2009-07-29 JP JP2011520506A patent/JP6022159B2/ja active Active
-
2011
- 2011-01-28 DO DO2011000031A patent/DOP2011000031A/es unknown
- 2011-01-31 IL IL210977A patent/IL210977A0/en unknown
- 2011-02-03 ZA ZA2011/00889A patent/ZA201100889B/en unknown
- 2011-02-11 MA MA33605A patent/MA32554B1/fr unknown
- 2011-02-23 CO CO11022213A patent/CO6341567A2/es not_active Application Discontinuation
-
2014
- 2014-11-10 SM SM201400170T patent/SMT201400170B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201400170B (it) | 2015-01-15 |
| DK2318042T3 (da) | 2014-11-10 |
| BRPI0916732B1 (pt) | 2021-06-29 |
| CO6341567A2 (es) | 2011-11-21 |
| CA2732436C (en) | 2018-01-16 |
| DOP2011000031A (es) | 2011-02-28 |
| NZ590919A (en) | 2012-10-26 |
| WO2010012780A1 (en) | 2010-02-04 |
| EP2318042B1 (en) | 2014-08-20 |
| MA32554B1 (fr) | 2011-08-01 |
| KR20110053340A (ko) | 2011-05-20 |
| US20110189229A1 (en) | 2011-08-04 |
| CN102159239A (zh) | 2011-08-17 |
| PL2318042T3 (pl) | 2015-02-27 |
| MX2011001218A (es) | 2011-03-15 |
| AU2009275909A1 (en) | 2010-02-04 |
| BRPI0916732A2 (pt) | 2017-01-31 |
| RS53607B1 (sr) | 2015-04-30 |
| SI2318042T1 (sl) | 2014-12-31 |
| CA2732436A1 (en) | 2010-02-04 |
| EP2318042A1 (en) | 2011-05-11 |
| PT2318042E (pt) | 2014-11-05 |
| JP2011529475A (ja) | 2011-12-08 |
| PE20110327A1 (es) | 2011-06-29 |
| IL210977A0 (en) | 2011-04-28 |
| HRP20141063T1 (hr) | 2015-01-02 |
| ES2519490T3 (es) | 2014-11-07 |
| ZA201100889B (en) | 2012-04-25 |
| EA201170264A1 (ru) | 2011-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100528226C (zh) | 人乳头瘤病毒的病毒样颗粒 | |
| JP4546092B2 (ja) | ワクチン | |
| CA2732436C (en) | Vaccine against hpv | |
| MX2011013744A (es) | Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv. | |
| CA2566620C (en) | Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52 | |
| KR101359943B1 (ko) | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 | |
| CA2606092A1 (en) | Vaccine | |
| US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
| CN101217976A (zh) | 疫苗 | |
| Mandić | Prophylactic HPV vaccines. | |
| CA2606206A1 (en) | Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120730 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140203 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140303 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140501 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150324 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160617 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160719 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161005 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6022159 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |